Myeloproliferative Neoplasms News

The addition of pevonedistat to azacitidine prolonged EFS among patients with higher-risk myelodysplastic syndrome, according to results of a phase 2 study presented at Society of Hematologic Oncology Annual Meeting.

Myeloablative fludarabine and busulfan conditioning appeared effective for patients with myelofibrosis undergoing allogeneic stem cell transplant, according to results presented at Society of Hematologic Oncology Annual Meeting.

Recent cytotoxic chemotherapy treatment did not appear associated with adverse COVID-19 outcomes for patients with cancer, according to results of a retrospective study published in Journal of Clinical Oncology.

Antithymocyte globulin decreased incidence of acute graft-versus-host-disease after allogeneic stem cell transplantation from an HLA-matched sibling donor, according to randomized study results published in Journal of Clinical Oncology.

The 62nd annual ASH Annual Meeting and Exposition will not be held in San Diego as planned.

The FDA granted breakthrough therapy designation to pevonedistat for patients with higher-risk myelodysplastic syndrome, according to a press release from the drug’s manufacturer.

A randomized phase 3 study designed to evaluate ruxolitinib for chronic graft-versus-host disease met its primary and key secondary endpoints.

Three organizations awarded grants totaling $6.75 million to fund research into blood cancers.

The FDA approved the oral combination of decitabine and cedazuridine for treatment of adults with myelodysplastic syndrome.

Eunice Wang, MD, has been named medical director of infusion services at Roswell Park Comprehensive Cancer Center.